Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Morgan, RD; Clamp, AR; White, DJ; Price, M; Burghel, GJ; Ryder, WDJ; Mahmood, RD; Murphy, AD; Hasan, J; Mitchell, CL; Salih, Z; Wheeler, C; Buckley, E; Truelove, J; King, G; Ainaoui, Y; Bhaskar, SS; Shaw, J; Evans, DGR; Kilerci, B; Pearce, SP; Brady, G; Dive, C; O'Connor, JPB; Wallace, AJ; Rothwell, DG; Edmondson, RJ; Jayson, GC

Morgan, RD (通讯作者)，Christie NHS Fdn Trust, Manchester M20 4BX, England.

CLINICAL CANCER RESEARCH, 2023; 29 (14): 2602

Abstract

Purpose: A single maintenance course of a PARP inhibitor (PARPi) improves progression-free survival (PFS) in germline BRCA1/2- mutant high-grade serou......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索